Fibroblast growth factor 21:a novel metabolic regulator from pharmacology to physiology
Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology作者机构：Department of Endocrinology and MetabolismShanghai Jiao Tong University Affiliated Sixth People’s HospitalShanghai Diabetes InstituteShanghai Clinical Center of DiabetesShanghai 200233China
出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)
年 卷 期：2013年第7卷第1期
页 面：25-30页
核心收录：
基 金：This work was supported by the National Basic Research Program of China(973 Program,2011CB504001) General Program of National Natural Science Foundation(Grant No.81170379) Key Project from Science and Technology Commission of Shanghai Municipality(09DZ1950202)to W.J. Young Scientists Fund of National Natural Science Foundation(Grant No.81200292) Science and Technology Fund of Shanghai Jiao Tong University School of Medicine to H.L.
主 题：FGF21 metabolism pharmacology physiology clinical relevance
摘 要：Fibroblast growth factor 21(FGF21)is a member of the fibroblast growth factor family.It actually functions as endocrine hormones but does not regulate cell growth and differentiation.It is demonstrated that FGF21 acts on multiple tissue to coordinate carbohydrate and lipid metabolism,including enhancing insulin sensitivity,decreasing triglyceride concentrations,causing weight loss,ameliorating obesity-associated hyperglycemia and hyperlipidemia.Moreover,FGF21 also plays important roles in some physiological processes,such as fasting and feeding,growth hormone axis and thermogenic function of brown adipose tissue.Clinical relevance of FGF21 in humans is still unclear,and the basis and consequences of increased FGF21 in metabolic disease remain to be determined.Both the pharmacological actions and physiological roles make FGF21 attractive drug candidates for treating metabolic disease,but some questions remain to be answered.This article concentrates on recent advances in our understanding of FGF21.
维普期刊数据库